Deuruxolitinib Phosphate is a small molecule commercialized by Concert Pharmaceuticals, with a leading Phase III program in Alopecia Areata. According to Globaldata, it is involved in 21 clinical trials, of which 18 were completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Deuruxolitinib Phosphate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Deuruxolitinib Phosphate is expected to reach an annual total of $154 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Deuruxolitinib Phosphate Overview

Deuruxolitinib phosphate (CTP-543, Deuterated Ruxolitinib) is under development for the treatment of moderate to severe alopecia areata. It is a deuterium-modified analog of ruxolitinib administered orally. It acts by targeting the Janus kinases (JAK1 and JAK2). It is developed based on the DCE (deuterated chemical entity) platform.

Concert Pharmaceuticals Overview

Concert Pharmaceuticals (Concert Pharma) is a late-stage clinical biotechnology company. It discovers and develops drugs for impacted patient care and addresses medical needs. The company develops its products using its deuterated chemical entity (DCE) platform for the treatment of autoimmune dermatological conditions, which includes alopecia areata. The alopecia areata occurs when the immune system attacks the hair follicles and is characterized as non-scarring hair loss. It also develops CTP-543, which is an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of adults with moderate to severe alopecia areata. The company has operations in the US, the UK and Ireland. Concert Pharma is headquartered in Lexington, Massachusetts, the US.

The company reported revenues of (US Dollars) US$32.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$7.9 million in FY2020. The operating loss of the company was US$77.5 million in FY2021, compared to an operating loss of US$72.7 million in FY2020. The net loss of the company was US$80.1 million in FY2021, compared to a net loss of US$74.8 million in FY2020.

For a complete picture of Deuruxolitinib Phosphate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.